Briquilimab is under clinical development by Jasper Therapeutics and currently in Phase I for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). According to GlobalData, Phase I drugs for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) have a 71% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Briquilimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Briquilimab overview

Briquilimab (AMG-191) is under development for the treatment of fanconi anemia,  myelodysplastic syndrome, severe combined immunodeficiency, acute myeloid leukemia, sickle cell disease, chronic granulomatous disease (CGD) and Gaucher disease type 1. The drug candidate acts by targeting stem cell growth factor receptor Kit. It is a humanized anti-c-Kit monoclonal antibody. It is administered through intravenous route. It was also under development for the treatment of inflammatory diseases such as idiopathic pulmonary fibrosis (IPF).

Jasper Therapeutics overview

Jasper Therapeutics focuses on development and commercialization of hematopoietic stem cell transplants. It develops and commercializes stem cell engineering for expanded use of stem cell transplantation. The company pipeline products are JSP191 is in clinical development that clears hematopoietic stem cells from bone marrow. It also engineered hematopoietic stem cells(eHSCs) platform to address the limitations of transplant grafts and unlock the potential of stem cells. Jasper Therapeutics is headquartered in ReedWood, California, The US.

For a complete picture of Briquilimab’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.